Glaukos Corporation (GKOS) Eye Treatment Epioxa Poised for Strong Market Uptake, Says Stifel

Core Insights - Glaukos Corporation (NYSE:GKOS) is positioned as a leading investment opportunity in the medical device sector, particularly with the upcoming PDUFA date for its Epioxa medication on October 20 [1] - Stifel has reaffirmed a Buy rating and a price target of $115 for Glaukos, supported by a survey indicating strong uptake and volume projections for Epioxa among ophthalmologists [1][2] Company Overview - Glaukos Corporation specializes in developing innovative treatments for eye diseases, including glaucoma and corneal issues, utilizing micro-invasive surgical instruments and drug delivery systems to improve patient outcomes [3] Market Potential - The findings from Stifel's survey suggest that Epioxa is expected to capture a significant share of the corneal cross-linking (CXL) operation volume, contributing to market growth [2] - The survey also indicates minimal patient warehousing prior to Epioxa's launch, which alleviates previously identified concerns by Glaukos management and supports an optimistic outlook for Corneal Health revenue in the latter half of 2025 and into 2026 [2]